Pharvaris Sees $74 Analyst Target, $132.3M Raise and 2026 HAE Data
UBS analyst set a $74 price target for Pharvaris, implying 63.2% upside from recent $31.25 levels. The company raised $132.3 million in an underwritten offering, holds €247 million cash, and targets CHAPTER-3 data in Q3 2026 with an HAE treatment NDA filing in H1 2026.
1. Analyst Sets Bullish Price Target
A recent UBS analyst assigned Pharvaris a $74 price target, representing potential upside of roughly 63.2% from the stock’s trading level near $31.25. This upgrade underscores growing confidence in the company’s late-stage pipeline and commercial prospects for its HAE treatment candidate.
2. Strengthened Financial Position
Pharvaris completed an underwritten offering that generated $132.3 million in fresh capital and reported €247 million in cash as of March 31, 2026. The additional funds extend its operational runway into 2028, supporting ongoing development programs and potential commercial launch preparations.
3. Clinical Milestones on Track
The company plans to release pivotal data from its CHAPTER-3 study in the third quarter of 2026, a key catalyst for regulatory review. Pharvaris also remains on schedule to submit a New Drug Application for its on-demand hereditary angioedema treatment during the first half of 2026.